An inquiry into saffron's effects on dyslipidemia
Phase 2
- Conditions
- Dyslipidemia.Pure hyperglyceridaemia
- Registration Number
- IRCT2016083017756N4
- Lead Sponsor
- Vice-Chancellery for Research and Technology, Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
patients with lipid disorders (HDL=40; LDL=130; TG=200; total cholesterol=200 mg/dl); Not receiving antidyslipidemic drugs; age from 30 to 60 years; no history of stroke or heart surgery; lack of genetic dyslipidemic disease; provision of informed consent.
Exclusion criteria: use of antidyslipidemic drugs during the study; incidence of myocardial infarction or heart surgery during the study; occurrence of unexpected circumstances for the participant such as an accident, death, etc.; failure to use saffron or placebo pills during the study, even for a single day
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Triglyceride. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;Total cholesterol. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;LDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.;HDL. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.
- Secondary Outcome Measures
Name Time Method iver enzymes. Timepoint: Before and 28 days after intervention. Method of measurement: Pars Azmoon kit and Autoanalyzer.